Sarah Hart

Dr. Sarah Hart

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in Nature
Verified
Journal Article
Closed access
RBRichard Broadhead
Richard Broadhead
HDHelen R. Dawe
Helen R. Dawe
HFHelen Farr
Helen Farr
SGSamantha Griffiths
Samantha Griffiths
SHSarah Hart
Sarah Hart
KGKeith Gull
Keith Gull

30 April 2007 in Journal of Biology
Verified
Journal Article
Open access
PDF file
JMJuan Carlos Martinez-Castrillo
Juan Carlos Martinez-Castrillo
LZLeo Zeef
Leo Zeef
DHDavid C Hoyle
David C Hoyle
NZNianshu Zhang
Nianshu Zhang
AHAndrew Hayes
Andrew Hayes
SOStephen G Oliver
Stephen G Oliver
Background: Cell growth underlies many key cellular and developmental processes, yet a limited number of studies have been carried out on cell-growth regulation. Comprehensive studies at the transcriptional, proteomic and metabolic levels under defined controlled conditions are currently lacking. Results: Metabolic control analysis is being exploited in a systems biology study of the eukaryotic cell. Using chemostat culture, we have measured the impact of changes in flux (growth rate) on the transcriptome, proteome, endometabolome and exometabolome of the yeast Saccharomyces cerevisiae. Each functional genomic level shows clear growth-rate-associated trends and discriminates between carbon-sufficient and carbon-limited conditions. Genes consistently and significantly upregulated with increasing growth rate are frequently essential and encode evolutionarily conserved proteins of known function that participate in many protein-protein interactions. In contrast, more unknown, and fewer essential, genes are downregulated with increasing growth rate; their protein products rarely interact with one another. A large proportion of yeast genes under positive growth-rate control share orthologs with other eukaryotes, including humans. Significantly, transcription of genes encoding components of the TOR complex (a major controller of eukaryotic cell growth) is not subject to growth-rate regulation. Moreover, integrative studies reveal the extent and importance of post-transcriptional control, patterns of control of metabolic fluxes at the level of enzyme synthesis, and the relevance of specific enzymatic reactions in the control of metabolic fluxes during cell growth. Conclusion: This work constitutes a first comprehensive systems biology study on growth-rate control in the eukaryotic cell. The results have direct implications for advanced studies on cell growth, in vivo regulation of metabolic fluxes for comprehensive metabolic engineering, and for the design of genome-scale systems biology models of the eukaryotic cell.

14 May 2003 in Analytical Chemistry
Verified
Journal Article
Closed access
ATAndrew J. Thompson
Andrew J. Thompson
SHSarah Hart
Sarah Hart
CFClemens M. Franz
Clemens M. Franz
KBKarin Barnouin
Karin Barnouin
ARAnne Ridley
Anne Ridley
Rainer CramerRainer Cramer
Rainer Cramer

14 July 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
EWElizabeth de Wolf
Elizabeth de Wolf
MAMarwan Abdullah
Marwan Abdullah
SJStefanie M. Jones
Stefanie M. Jones
KMKaren Menezes
Karen Menezes
DMDarren M. Moss
Darren M. Moss
Alan RichardsonAlan Richardson
Alan Richardson
Pre-clinical and retrospective studies of patients using statins to reduce plasma cholesterol have suggested that statins may be useful to treat cancer. However, prospective clinical trials have yet to demonstrate significant efficacy. We have previously shown that this is in part because a hydrophobic statin with a long half-life is necessary. Pitavastatin, the only statin with this profile, has not undergone clinical evaluation in oncology. The target of pitavastatin, hydroxymethylglutarate coenzyme-A reductase (HMGCR), was found to be over-expressed in all ovarian cancer cell lines examined and upregulated by mutated TP53, a gene commonly altered in ovarian cancer. Pitavastatin-induced apoptosis was blocked by geranylgeraniol and mevalonate, products of the HMGCR pathway, confirming that pitavastatin causes cell death through inhibition of HMGCR. Solvent extracts of human and mouse food were also able to block pitavastatin-induced apoptosis, suggesting diet might influence the outcome of clinical trials. When nude mice were maintained on a diet lacking geranylgeraniol, oral pitavastatin caused regression of Ovcar-4 tumour xenografts. However, when the animal diet was supplemented with geranylgeraniol, pitavastatin failed to prevent tumour growth. This suggests that a diet containing geranylgeraniol can limit the anti-tumour activity of pitavastatin and diet should be controlled in clinical trials of statins.

1 September 2002 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Closed access
SHSarah Hart
Sarah Hart
MWM. D. Waterfield
M. D. Waterfield
ABA. L. Burlingame
A. L. Burlingame
Rainer CramerRainer Cramer
Rainer Cramer

17 September 2004 in BMC Genomics
Verified
Journal Article
Open access
KGKevin Garwood
Kevin Garwood
TMThomas McLaughlin
Thomas McLaughlin
CGChris Garwood
Chris Garwood
SJScott Joens
Scott Joens
NMNorman Morrison
Norman Morrison
NPNorman W Paton
Norman W Paton
Background: Proteomics is rapidly evolving into a high-throughput technology, in which substantial and systematic studies are conducted on samples from a wide range of physiological, developmental, or pathological conditions. Reference maps from 2D gels are widely circulated. However, there is, as yet, no formally accepted standard representation to support the sharing of proteomics data, and little systematic dissemination of comprehensive proteomic data sets. Results: This paper describes the design, implementation and use of a P roteome E xperimental D ata R epo sitory (PEDRo), which makes comprehensive proteomics data sets available for browsing, searching and downloading. It is also serves to extend the debate on the level of detail at which proteomics data should be captured, the sorts of facilities that should be provided by proteome data management systems, and the techniques by which such facilities can be made available. Conclusions: The PEDRo database provides access to a collection of comprehensive descriptions of experimental data sets in proteomics. Not only are these data sets interesting in and of themselves, they also provide a useful early validation of the PEDRo data model, which has served as a starting point for the ongoing standardisation activity through the Proteome Standards Initiative of the Human Proteome Organisation.